MIRA Pharma reports preclinical data showing Mira-55 differentiated from THC, anxiolytic effect

MIRA PHARMACEUTICALS, INC.

Mira-55 did not produce THC-like locomotor suppression or catalepsy in standard preclinical assays.
Modest body temperature reduction from Mira-55 was not reversed by CB1 antagonist rimonabant, indicating distinct mechanism.
Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity of rimonabant; THC showed no anxiolysis.
Data builds on March 2026 results; company advancing Mira-55 toward IND for chronic inflammatory pain.
No psychoactivity or CNS side effects observed; candidate designed to avoid THC liabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.